We are pleased to announce that a tissue graft patent has been granted by the United States Patent and Trademark Office (USPTO) for the personalized bioengineered human skin tissue therapy developed by CUTISS.
The patent (U.S. Patent no. 10,953,140 B2) has been granted to University of Zurich (UZH) where the founders of CUTISS worked at the time of the patent filing (2014), and is exclusively licensed to CUTISS.
This patent strengthens the company’s intellectual property position in human tissue graft technologies in the US (in addition to other markets), and complements the existing patent covering the method and production process which is also granted across multiple markets.
CUTISS’s first skin tissue therapy product denovoSkin is currently in Phase IIb clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA.